Belumosudil Versus Ruxolitinib for Steroid-Refractory or Breakthrough Hepatic cGVHD

NCT07794514 | Recruiting

• 1 other identifier: BR-HEP-CGVHD
• Study Type: interventional
• Target: 170
• Locations: 1 country
• Sites: 1

Brief Summary

This prospective, randomized, open-label, multicenter trial aims to compare second-line treatment strategies for hepatic cGVHD after allo-HSCT. Ruxolitinib and belumosudil are both effective for cGVHD, but no head-to-head comparison specifically in hepatic cGVHD has been reported. Two cohorts are enrolled: Cohort 1 comprises patients with steroid-refractory hepatic cGVHD without prior ruxolitinib or belumosudil exposure, randomized to receive either agent. Cohort 2 includes patients who develop new-onset hepatic cGVHD after ≥4 weeks of therapy with ruxolitinib or belumosudil for other-organ cGVHD (stable for ≥2 weeks), or patients with non-response/progression on either agent for hepatic cGVHD; these patients will be switched to the opposite drug. Key questions include: • In steroid-refractory hepatic cGVHD, does 24-week hepatic overall response rate differ between belumosudil and ruxolitinib? • What is the hepatic response rate after drug switching in Cohort 2? • How do the two agents compare in safety and tolerability for hepatic cGVHD? • What are their impacts on corticosteroid tapering, failure-free survival, and long-term outcomes? Participants will: • Receive assigned treatment per cohort and randomization • Undergo regular efficacy/safety monitoring, including hepatic cGVHD scoring, liver function tests, and adverse event recording • Provide peripheral blood samples at baseline and multiple on-treatment time points for exploratory biomarker analysis • Complete 24-week primary efficacy assessment with follow-up until progression or discontinuation Primary endpoint is 24-week hepatic overall response rate (CR+PR, per 2014 NIH cGVHD criteria). Secondary endpoints include duration of response, failure-free survival, corticosteroid tapering rate, safety (AE/SAE incidence), liver function improvement, and patient-reported outcomes. This head-to-head comparison will provide high-level evidence for selecting second-line and beyond therapies for hepatic cGVHD.

Conditions

Hematopoietic Stem Cell Transplantation (HSCT); cGVHD; Hepatic cGVHD; Belumosudil; Ruxolitinib

Keywords

Hematopoietic Stem Cell Transplantation; Hepatic cGVHD; Belumosudil; Ruxolitinib

Outcome Measures

Primary Outcomes (1)

• Overall Response Rate (ORR) for Hepatic cGVHD at Week 24

  at Week 24 after treatment

Secondary Outcomes (6)

• Best overall response (BOR)

  Assessed continuously throughout the study from the date of randomization，up to 24 weeks after treatment

• Duration of response (DOR)

  From first response to progression/death, whichever came first, assessed up to 2 years after the date of randomization

• Incidence of adverse events (AEs)

  Continuous monitoring from first dose to 30 days after last dose

• Quality of life (QoL) score

  Assessed at baseline, Week 12, Week 24, and end of treatment

• Overall survival (OS)

  From date of randomization until the date of death from any cause, whichever came first, assessed up to 2 years after the date of randomization.

Study Arms (4)

Ruxolitinib Group

ACTIVE COMPARATOR

Participants assigned to this arm will receive ruxolitinib administered orally at the standard approved dose and schedule for the treatment of steroid-refractory hepatic chronic graft-versus-host disease (cGVHD).

Drug: Ruxolitinib treatment

Belumosudil Group

EXPERIMENTAL

Participants assigned to this arm will receive belumosudil administered orally at the standard approved dose and schedule for the treatment of steroid-refractory hepatic chronic graft-versus-host disease (cGVHD).

Drug: Belumosudil treatment

Belumosudil Switch to Ruxolitinib Group

OTHER

Participants with breakthrough hepatic cGVHD on stable belumosudil therapy for non-hepatic cGVHD who develop new-onset hepatic cGVHD or have no response/progression on belumosudil, not attributable to other etiologies, and with no prior ruxolitinib exposure, will discontinue belumosudil and cross over to ruxolitinib.

Drug: Belumosudil Switch to Ruxolitinib

Ruxolitinib Switch to Belumosudil Group

OTHER

Participants with breakthrough hepatic cGVHD on stable ruxolitinib therapy for non-hepatic cGVHD who develop new-onset hepatic cGVHD or have no response/progression on ruxolitinib, not attributable to other etiologies, and with no prior belumosudil exposure, will discontinue ruxolitinib and cross over to belumosudil.

Drug: Ruxolitinib Switch to Belumosudil

Interventions

Ruxolitinib treatment DRUG

Ruxolitinib treatment

Ruxolitinib Group

Belumosudil treatment DRUG

Belumosudil treatment

Belumosudil Group

Belumosudil Switch to Ruxolitinib DRUG

Belumosudil Switch to Ruxolitinib

Belumosudil Switch to Ruxolitinib Group

Ruxolitinib Switch to Belumosudil DRUG

Ruxolitinib Switch to Belumosudil

Ruxolitinib Switch to Belumosudil Group

Eligibility Criteria

• Age: 12 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Age ≥ 12 years at time of signing informed consent.
• Received allogeneic hematopoietic stem cell transplantation.
• Meets 2014 NIH consensus criteria for hepatic cGVHD (≥1 of: total bilirubin \> 2×ULN, ALP \> 2×ULN, ALT \> 2×ULN, or liver biopsy-proven cGVHD-related injury), after excluding other causes.
• ECOG performance status ≤ 2.
• Able to take oral medication.
• Life expectancy ≥ 6 months.
• Adequate organ function: ANC ≥ 1.0×10⁹/L, platelets ≥ 50×10⁹/L, creatinine clearance ≥ 30 mL/min.
• Female patients of childbearing potential have negative pregnancy test and agree to effective contraception during study and for 6 months after last dose; male patients agree to same.
• Willing and able to provide written informed consent and comply with study requirements.
• Cohort 1 (Steroid-refractory): Progressive disease on stable steroids (1 mg/kg/day) within 1-2 weeks prior to screening, or persistent cGVHD without improvement after ≥4 weeks of prednisone (or equivalent) \> 0.5 mg/kg/day. (Prior aGVHD JAK inhibitor use allowed if stopped ≥8 weeks.).
• Cohort 2 (Breakthrough hepatic cGVHD): Patients on stable (≥2 weeks) ruxolitinib or belumosudil monotherapy for non-hepatic cGVHD for ≥4 weeks, who develop new-onset hepatic cGVHD or experience no response or progression on current therapy for hepatic cGVHD, not attributable to other etiologies (e.g., viral hepatitis, drug-induced liver injury, biliary obstruction, iron overload, alcoholic liver disease), with no prior exposure to the alternative study agent.

You may not qualify if:

• Receiving newly initiated systemic cGVHD therapy other than corticosteroids and calcineurin inhibitors (CNIs); corticosteroids and CNIs must be on a stable regimen for ≥2 weeks prior to screening.
• Uncontrolled active acute GVHD (≥ grade 2).
• Active viral hepatitis or HIV infection.
• Liver function abnormalities due to other causes, including but not limited to drug-induced liver injury, autoimmune hepatitis, alcoholic liver disease, biliary obstruction, VOD/SOS, iron overload, Gilbert's syndrome, or hemolysis.
• Severe cardiovascular or cerebrovascular disease, including but not limited to: NYHA class ≥3, uncontrolled hypertension, severe arrhythmia, or myocardial infarction/stroke within 6 months.
• Respiratory failure requiring mechanical ventilation, resting pulse oxygen saturation \<90%, or severe/uncontrolled pulmonary cGVHD or other respiratory disease that may significantly affect patient safety or study assessment, per investigator judgment.
• Inability to take oral medication, severe gastrointestinal dysfunction (NCI CTCAE v5.0 ≥ grade 3), severe GI cGVHD requiring parenteral nutrition, daily diarrhea \>1 L, or any other condition significantly affecting GI absorption.
• Significant neurological or psychiatric history (including epilepsy or dementia) that makes the subject unsuitable for participation.
• Relapsed primary malignancy or PTLD.
• History of other malignancies, except cured and fully resected basal or squamous cell skin carcinoma, surgically cured cervical carcinoma in situ, resected ductal carcinoma in situ of the breast, prostate cancer (Gleason \<6 with stable PSA \>12 months), or other malignancies with no evidence of recurrence after curative treatment.
• ECG abnormality: QTcF \>450 ms (male) or \>470 ms (female) at screening.
• Known alcohol or drug dependence.
• Pregnant or breastfeeding women.
• Allergy to study drug or its excipients.
• Any other condition that may affect patient safety or compliance, per investigator judgment.

Sponsors & Collaborators

• First Affiliated Hospital of Zhejiang University: lead
• Union Hospital, Tongji Medical College, Huazhong University of Science and Technology: collaborator
• The First Affiliated Hospital of Zhengzhou University: collaborator
• Ruijin Hospital: collaborator
• Tongji Hospital: collaborator
• Peking University People's Hospital: collaborator
• First Affiliated Hospital of Ningbo University: collaborator

Study Sites (1)

The First Affiliated Hospital of Zhejiang University School of Medicine

Hangzhou, Zhejiang, 310006, China

RECRUITING

Related Publications (14)

• Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, Palmer J, Weisdorf D, Treister NS, Cheng GS, Kerr H, Stratton P, Duarte RF, McDonald GB, Inamoto Y, Vigorito A, Arai S, Datiles MB, Jacobsohn D, Heller T, Kitko CL, Mitchell SA, Martin PJ, Shulman H, Wu RS, Cutler CS, Vogelsang GB, Lee SJ, Pavletic SZ, Flowers ME. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant. 2015 Mar;21(3):389-401.e1. doi: 10.1016/j.bbmt.2014.12.001. Epub 2014 Dec 18.

  PMID: 25529383 BACKGROUND

• Hall K, Lazaryan A, van der Laan M, Lee C, Logan AC, Gruber S, Kabadi S, Khan I, Nicholls C, Rota L, Nikai E, Ponomareva E, Koumas A, Waller EK. Efficacy and safety of belumosudil as compared with best available therapy for the treatment of cGVHD in the United States. Blood Adv. 2026 Feb 10;10(3):682-693. doi: 10.1182/bloodadvances.2025015832.

  PMID: 40875591 BACKGROUND

• Lee SJ, Pavletic S, Blazar BR, Yao Y, Ji R, Marshall K, Cutler C; KD025-208 and ROCKstar Study Investigators. Belumosudil for Chronic Graft-Versus-Host Disease: Analysis of Long-Term Results from the KD025-208 and ROCKstar Studies. Transplant Cell Ther. 2025 Jul;31(7):434.e1-434.e10. doi: 10.1016/j.jtct.2025.04.020. Epub 2025 May 1.

  PMID: 40318736 BACKGROUND

• Ibrahimova A, Bidgoli A, Ashraf A, Krogman A, Klink G, Teusink-Cross A, Schoettler ML, Davies SM, Khandelwal P. Real world experience using belumosudil for treatment of chronic graft versus host disease in children and young adults. Bone Marrow Transplant. 2026 Apr;61(4):487-489. doi: 10.1038/s41409-025-02795-9. Epub 2026 Jan 21. No abstract available.

  PMID: 41566004 BACKGROUND

• Nalkurthi C, Schroder WA, Melino M, Irvine KM, Nyuydzefe M, Chen W, Liu J, Teng MWL, Hill GR, Bertolino P, Blazar BR, Miller GC, Clouston AD, Zanin-Zhorov A, MacDonald KPA. ROCK2 inhibition attenuates profibrogenic immune cell function to reverse thioacetamide-induced liver fibrosis. JHEP Rep. 2021 Oct 6;4(1):100386. doi: 10.1016/j.jhepr.2021.100386. eCollection 2022 Jan.

  PMID: 34917911 BACKGROUND

• Modi B, Ngo D, Chen J, Yang D, Shan H, Sandhu K, Rashid N, Amanam I, Otoukesh S, Nakamura R, Ali H, Salhotra A. Belumosudil for the treatment of chronic graft-versus-host disease: a single center real-world experience. Bone Marrow Transplant. 2025 Apr;60(4):555-557. doi: 10.1038/s41409-024-02498-7. Epub 2025 Feb 4. No abstract available.

  PMID: 39905130 BACKGROUND

• Michonneau D, Malard F, Le Grand S, Magro L, D'Aveni M, Tudesq JJ, Villate A, Meunier M, Maillard N, Castilla-Llorente C, Marcais A, Cabrera Q, Huynh A, Menard AL, Forcade E, Labussiere-Wallet H, Raus N, Loschi M. Efficacy and safety of belumosudil for treatment of cGVHD: multicenter retrospective analysis of the French cohort of the compassionate use program, on behalf of the French Society of Bone Marrow Transplantation and Cellular Therapy. Bone Marrow Transplant. 2025 Jun;60(6):779-786. doi: 10.1038/s41409-025-02554-w. Epub 2025 Apr 1.

  PMID: 40169928 BACKGROUND

• Jagasia M, Lazaryan A, Bachier CR, Salhotra A, Weisdorf DJ, Zoghi B, Essell J, Green L, Schueller O, Patel J, Zanin-Zhorov A, Weiss JM, Yang Z, Eiznhamer D, Aggarwal SK, Blazar BR, Lee SJ. ROCK2 Inhibition With Belumosudil (KD025) for the Treatment of Chronic Graft-Versus-Host Disease. J Clin Oncol. 2021 Jun 10;39(17):1888-1898. doi: 10.1200/JCO.20.02754. Epub 2021 Apr 20.

  PMID: 33877856 BACKGROUND

• Inamoto Y, Kato K, Kawakita T, Onishi Y, Matsuoka KI, Shiratori S, Ikegame K, Hiramoto N, Toyosaki M, Katayama Y, Murayama S, Sasagawa Y, Maeda Y, Hatake K, Teshima T. An open-label study of belumosudil, a selective ROCK2 inhibitor, as second or subsequent line of therapy for steroid-dependent/steroid-resistant chronic GVHD. Am J Hematol. 2024 Oct;99(10):1917-1926. doi: 10.1002/ajh.27424. Epub 2024 Jun 27.

  PMID: 38934629 BACKGROUND

• Cutler C, Lee SJ, Arai S, Rotta M, Zoghi B, Lazaryan A, Ramakrishnan A, DeFilipp Z, Salhotra A, Chai-Ho W, Mehta R, Wang T, Arora M, Pusic I, Saad A, Shah NN, Abhyankar S, Bachier C, Galvin J, Im A, Langston A, Liesveld J, Juckett M, Logan A, Schachter L, Alavi A, Howard D, Waksal HW, Ryan J, Eiznhamer D, Aggarwal SK, Ieyoub J, Schueller O, Green L, Yang Z, Krenz H, Jagasia M, Blazar BR, Pavletic S. Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study. Blood. 2021 Dec 2;138(22):2278-2289. doi: 10.1182/blood.2021012021.

  PMID: 34265047 BACKGROUND

• Zeiser R, Russo D, Ram R, Hashmi SK, Chakraverty R, Middeke JM, Musso M, Giebel S, Uzay A, Langmuir P, Hamad N, Burock K, Gowda M, Stefanelli T, Lee SJ, Teshima T, Locatelli F. Ruxolitinib in Patients With Corticosteroid-Refractory or Corticosteroid-Dependent Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of the Phase III REACH3 Study. J Clin Oncol. 2025 Aug 10;43(23):2566-2571. doi: 10.1200/JCO-24-02477. Epub 2025 Jun 25.

  PMID: 40561385 BACKGROUND

• Zeiser R, Polverelli N, Ram R, Hashmi SK, Chakraverty R, Middeke JM, Musso M, Giebel S, Uzay A, Langmuir P, Hollaender N, Gowda M, Stefanelli T, Lee SJ, Teshima T, Locatelli F; REACH3 Investigators. Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease. N Engl J Med. 2021 Jul 15;385(3):228-238. doi: 10.1056/NEJMoa2033122.

  PMID: 34260836 BACKGROUND

• Zeiser R, Lee SJ. Three US Food and Drug Administration-approved therapies for chronic GVHD. Blood. 2022 Mar 17;139(11):1642-1645. doi: 10.1182/blood.2021014448.

  PMID: 35081254 BACKGROUND

• Hematopoietic Stem Cell Application Group, Chinese Society of Hematology, Chinese Medical Association. [Chinese expert consensus on the diagnosis and treatment of chronic graft-versus-host disease (2024)]. Zhonghua Xue Ye Xue Za Zhi. 2024 Aug 14;45(8):713-726. doi: 10.3760/cma.j.cn121090-20240611-00217. Chinese.

  PMID: 39307718 BACKGROUND

Central Study Contacts

Fei Gao

CONTACT

+86 19857035073; gf0906@zju.edu.cn

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Vice Director, Bone Marrow Transplantation Center, the First Affiliated Hospital, School of Medicine, Zhejiang University

Study Record Dates

• First Submitted: August 25, 2026
• First Posted: August 31, 2026
• Study Start: October 1, 2026
• Primary Completion (Estimated): April 1, 2030
• Study Completion (Estimated): December 31, 2030
• Last Updated: August 31, 2026

Record last verified: 2026-08

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)